What is the appropriate workup for evaluating coagulation disorders that predispose to thrombosis?

Workup for Thrombophilia (Coagulation Disorders Prone to Blood Clots)

Do not routinely test all patients with venous thromboembolism (VTE) for thrombophilia; testing should be reserved for highly selected cases where results will change management, specifically unprovoked VTE in young patients (<40-50 years), unusual thrombosis sites, recurrent VTE, or family history suggesting strong thrombophilia. 1, 2

Who Should Be Tested

Testing is not indicated for:

• VTE provoked by surgery, immobility, or malignancy 2
• Arterial thrombosis with atherosclerosis risk factors 2
• Routine screening after a single provoked VTE 1

Testing should be considered for:

• Unprovoked VTE before age 40-50 1, 3
• Thrombosis at unusual sites (splanchnic, cerebral veins) 4
• Recurrent VTE episodes 1, 3
• VTE during pregnancy or with oral contraceptive use 1
• Strong family history suggesting inherited thrombophilia 2

The rationale is straightforward: heterozygous Factor V Leiden and prothrombin mutations only slightly increase recurrence risk and typically don't change anticoagulation duration decisions 2. The main value of testing is detecting strong thrombophilias (antithrombin deficiency, antiphospholipid syndrome, homozygous Factor V Leiden, double heterozygous mutations, protein C/S deficiency) that warrant long-term anticoagulation 2.

Critical Timing Considerations

Never test during acute thrombosis or while on anticoagulation 5. This is a major pitfall—one study found 51% of tests were inappropriately performed within one week of the thrombotic event, and 46% of abnormal results were never confirmed, potentially leading to incorrect lifelong diagnoses 5.

Optimal timing:

• Wait at least 2-4 weeks after acute event
• Ideally test when off anticoagulation (after completing initial 3-6 month treatment course)
• Warfarin falsely lowers protein C and S levels
• Heparin can lower antithrombin levels
• Acute thrombosis itself causes acute phase reactions affecting multiple parameters 5

Laboratory Panel

For inherited thrombophilias:

• Activated protein C resistance (APC-R) testing—if ratio <0.9, this confirms Factor V Leiden without genetic testing; borderline values (0.9-1.1) require PCR confirmation 3
• Prothrombin G20210A mutation (genetic test) 1, 6
• Antithrombin activity 6, 3
• Protein C activity 6, 3
• Protein S activity (free and total) 6, 3

For acquired thrombophilias:

• Lupus anticoagulant 1
• Anticardiolipin antibodies (IgG and IgM) 1
• Anti-β2-glycoprotein-1 antibodies 1

For splanchnic vein thrombosis specifically:

• JAK2V617F mutation (present in 20-40% of splanchnic thrombosis even without overt myeloproliferative disease) 4
• Flow cytometry for paroxysmal nocturnal hemoglobinuria (PNH)—an important acquired risk factor for splanchnic thrombosis 4

Key Pitfalls to Avoid

1. Testing too early or during anticoagulation leads to false positives requiring lifelong unnecessary treatment 5

2. Failing to confirm abnormal results—54% of patients with abnormal tests in one study never had confirmatory testing 5. All abnormal results require repeat testing after stopping anticoagulation.

3. Ordering comprehensive panels indiscriminately—only 34% of tested patients in one analysis had appropriate indications 5. Implementation of testing guidelines reduced inappropriate testing by 84% 5.

4. Assuming testing changes management for common heterozygous mutations—it usually doesn't for Factor V Leiden or prothrombin mutations alone 2.

Clinical Decision Algorithm

Step 1: Determine if testing indication exists (unprovoked VTE, age <40-50, unusual site, recurrent, or strong family history)

Step 2: If yes, wait until patient completes initial 3-6 months anticoagulation and is off therapy for at least 2 weeks

Step 3: Order focused panel based on clinical scenario:

• Standard VTE: APC-R, prothrombin mutation, antithrombin, protein C, protein S, antiphospholipid antibodies
• Splanchnic thrombosis: Add JAK2 mutation and PNH testing 4

Step 4: Confirm all abnormal results with repeat testing

Step 5: Use results to counsel on:

• Long-term anticoagulation decisions (strong thrombophilias warrant indefinite therapy) 2
• Testing asymptomatic family members (particularly women of childbearing age) 2
• Avoidance of estrogen-containing contraceptives 1
• Peripartum anticoagulation planning 2

The evidence strongly supports selective rather than routine testing, with proper timing being absolutely critical to avoid misdiagnosis and inappropriate long-term anticoagulation 5.